A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This study is ongoing, but not recruiting participants.
First Posted: September 3, 2010
Last Update Posted: January 9, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||April 2021|
|Primary Completion Date:||July 2015 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||October 14, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.